Core Insights - Foghorn Therapeutics Inc. has appointed Ryan Maynard as Chief Financial Officer effective February 23, 2026, bringing over 25 years of executive experience in the biopharmaceutical sector [1][2][3] Company Overview - Foghorn Therapeutics is focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control® platform [4] Leadership and Experience - Ryan Maynard has a strong background in financial strategy and operational performance, having previously served as CFO at Cara Therapeutics, where he led financial strategy and strategic transactions [2][3] - He has raised over $1 billion through public and private financings and played a significant role in the FDA approval and commercial launch planning of TAVALISSE [3] - Maynard has also executed a reverse merger and raised $37.5 million through a non-dilutive royalty deal at Cara Therapeutics [3] Strategic Goals - The company aims to advance its first-in-class pipeline and is currently in dose escalation for its lead program in partnership with Lilly, while also preparing its selective degrader portfolio for clinical trials [2][3]

Core Insights - C4 Therapeutics has initiated the Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone, targeting relapsed/refractory multiple myeloma patients, with enrollment expected to complete by Q1 2027 [1][7] - The Phase 1b trial of cemsidomide in combination with elranatamab is set to begin in Q2 2026, supporting a regulatory strategy for accelerated approvals in multiple myeloma [2][3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, aiming to develop innovative therapies for difficult-to-treat diseases [10] - The company's lead candidate, cemsidomide, is an investigational oral IKZF1/3 degrader, showing promising safety and efficacy profiles in prior trials [4][10] Trial Details - The Phase 2 MOMENTUM trial is an open-label, single-arm study enrolling approximately 100 patients, evaluating cemsidomide at a dose of 100 µg, administered in a 14 days on and 14 days off schedule [2][5] - The primary endpoint of the trial is the overall response rate as per International Myeloma Working Group criteria, assessed by an independent review committee [5][9] Upcoming Milestones - Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is anticipated in mid-2026 [7] - The Phase 1b trial of cemsidomide with elranatamab will explore safety and preliminary efficacy, contributing to the broader development strategy for cemsidomide [6][3] Industry Context - Multiple myeloma is a rare blood cancer with approximately 36,000 new diagnoses annually in the U.S., highlighting the need for new therapeutic options as most patients eventually relapse [9] - IKZF1/3 degraders are foundational therapies in multiple myeloma treatment, and cemsidomide aims to enhance treatment efficacy and patient outcomes [9]

Core Insights - Loblaw Companies Limited plans to invest $2.4 billion in 2026 as part of a 5-year strategy to invest a total of $10 billion in Canadian communities by 2030 [1][3] - The investment aims to expand and renovate the store network, enhance supply chain capabilities, and create approximately 9,700 jobs across Canada [2][4] Investment Details - In 2026, Loblaw will open 70 new stores, including 34 Shoppers Drug Mart / Pharmaprix pharmacies and care clinics, and 31 No Frills and Maxi stores [2] - The company will also renovate 191 existing stores and continue construction of a 1.2 million square foot automated distribution center in Caledon, Ontario [2] Economic Impact - This investment reinforces Loblaw's role as a significant contributor to the Canadian economy and aims to provide better access to value for customers [3][4] - The job creation will be distributed across various regions: Eastern Canada (4 new stores, 600 jobs), Quebec (15 new stores, 1,985 jobs), Ontario (27 new stores, 3,775 jobs), and Western Canada (24 new stores, 3,400 jobs) [7]

Core Insights - TDG Gold Corp. has discovered a new lens of volcanogenic massive sulphide (VMS) mineralization, named the 4300 Zone, located below the past-producing Hidden Creek Mine at the Anyox Project in British Columbia [1][4][6]. Exploration and Discovery - The Hidden Creek Mine, operational from 1914 to 1935, produced 22 million tons of copper at a grade of 1.57% Cu before ceasing operations due to low metal prices during the Great Depression [2]. - Recent drilling by TDG has outlined the 4300 Zone, with drill hole ANY-25-002 intersecting a broad interval of massive sulphides grading 2.1% CuEQ over 25.08 meters, including higher-grade sub-intervals averaging 2.5% CuEQ over 14.80 meters [5][6]. - The 4300 Zone remains open for expansion in all directions, with additional drilling planned for 2026 [3][6]. Geological Context - The mineralization processes at Hidden Creek are typical of Besshi VMS systems, characterized by copper-rich deposits with subordinate concentrations of zinc, gold, silver, and cobalt [9][10]. - The geological environment consists of submarine volcanic rocks that host the VMS mineralization, with the 4300 Zone located at a depth of 900 meters below the surface [10][11]. Future Plans - TDG is well-funded and plans to continue exploration activities at Anyox, which has year-round tidewater access [4][6]. - Geophysical surveys have identified multiple new targets, and drilling of the 4300 Zone will resume in March 2026 after further data refinement [12][6].

Core Viewpoint - Plug Power Inc. is set to announce its 2025 fourth quarter and year-end results on March 2, 2026, highlighting its ongoing leadership in the hydrogen economy [1]. Group 1: Company Overview - Plug Power is a global leader in comprehensive hydrogen solutions, focusing on building a fully integrated ecosystem that includes production, storage, delivery, and power generation [3]. - The company is a first mover in the hydrogen industry, providing essential components such as electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure [3]. Group 2: Industry Position and Achievements - Plug Power has deployed over 72,000 fuel cell systems and 285 fueling stations, making it the largest user of liquid hydrogen [4]. - The company operates hydrogen plants in Georgia, Tennessee, and Louisiana, with a production capacity of 40 tons per day, ensuring a reliable and domestically produced hydrogen supply [4]. - Plug Power serves major global clients, including Walmart, Amazon, Home Depot, BMW, and BP, showcasing its significant role in advancing energy independence and decarbonization [5].

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event. About Apelli ...

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed re ...

TORONTO and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX:ILLM, OTCQB:ILLMF) (“illumin” or “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, announces that it will report its fourth quarter and year-end 2025 financial results before market open on Friday, March 13, 2026. Investors and analysts are invited to join a live webcast on Friday, March 13, 2026, at 8:30 AM ET, where CEO Simon C ...

Press Release February 23, 2026 Signify share repurchase periodic update Eindhoven, The Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 139,500 shares in the period February 13 to February 20, 2026. The shares were repurchased at an average price of EUR 20.06 per share and an aggregate amount of EUR 2.8 million. The repurchases were made as part of the company’s share repurchase program, which was announced on 13 February 2026. Details on the ...

European client will utilize PyroGenesis’ titanium powder in electron beam melting applicationsMONTREAL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the signing of a contract with a Scientific Aerospace Research Organization for the supply of titanium metal powder produced by PyroGenesis’ N ...